FierceBiotech 2026年1月8日 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
BioPharma Dive 2025年12月18日 Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Endpoints News 2025年12月18日 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
FierceBiotech 2025年12月11日 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Endpoints News 2025年12月11日 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported